David PierceSummaryAffiliation: Shire BioChem Inc Publications
| Collaborators |
Detail Information
Publications
Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom studyDavid Pierce
Shire Pharmaceutical Development Ltd, Basingstoke, United Kingdom
J Child Adolesc Psychopharmacol 18:355-64. 2008..To evaluate the pharmacokinetic properties of the methylphenidate transdermal system (MTS) in pediatric patients diagnosed with ADHD (attention-deficit/hyperactivity disorder) in a laboratory school setting...- Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorderDavid Pierce
Shire Pharmaceutical Development Ltd, Hampshire International Business Park, Chineham, Basingstoke, Hampshire, UK
J Clin Psychopharmacol 30:554-64. 2010..After all dosing, systemic exposure was greater in children compared with adolescents, consistent with lower body weight in children. Adverse events were mild to moderate for both formulations, and MTS dermal responses were mild... - The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriolDavid Pierce
Shire Pharmaceutical Development Ltd, Chineham, Hampshire, UK
Nephrol Dial Transplant 26:1615-21. 2011..Patients with CKD may require intravenous or oral active vitamin D. We investigated the effects of lanthanum carbonate and sevelamer carbonate on the bioavailability of oral calcitriol...